Audentes Therapeutics to Participate in Upcoming Investor Conferences
26 Novembre 2019 - 10:01PM
Business Wire
Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based
genetic medicines company focused on developing and commercializing
innovative products for serious rare neuromuscular diseases, today
announced that Natalie Holles, President and Chief Operating
Officer, will participate in the following investor conferences in
December:
31st Annual Piper Jaffray Healthcare Conference Fireside
Chat: Tuesday, December 3, 2019, at 10:00am ET New York, New
York
2nd Annual Evercore ISI HealthCONx Panel: “Gene Therapy
Manufacturing Powerhouses,” Wednesday, December 4, 2019, at 8:45am
ET Boston, Massachusetts
To access the live webcast of the Piper Jaffray fireside chat,
please visit the Events & Presentations page within the
Investors + Media section of the Audentes website. Following the
conference, a replay of the live webcast will be available on the
Audentes website for approximately 30 days. There is no webcast
available for the Gene Therapy Manufacutring Powerhouses panel at
the Evercore ISI HealthCONx conference.
About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a leading AAV-based
genetic medicines company focused on developing and commercializing
innovative products for serious rare neuromuscular diseases. We are
leveraging our AAV gene therapy technology platform and proprietary
manufacturing expertise to develop programs across three
modalities: gene replacement, vectorized exon skipping, and
vectorized RNA knockdown. Our product candidates are showing
promising therapeutic profiles in clinical and preclinical studies
across a range of neuromuscular diseases. Audentes is a focused,
experienced and passionate team driven by the goal of improving the
lives of patients.
For more information regarding Audentes, please visit
www.audentestx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191126005816/en/
Investor Contact: Andrew Chang
415.818.1033 achang@audentestx.com
Media Contact: Sarah Spencer
415.957.2020 sspencer@audentestx.com
Grafico Azioni Boundless Bio (NASDAQ:BOLD)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Boundless Bio (NASDAQ:BOLD)
Storico
Da Nov 2023 a Nov 2024